Program performance
What students demonstrated through program assessments across Years 1–3 and academic years.
What does the available evidence tell us about how well students are achieving the intended learning outcomes of this stream?
This workspace brings together what students demonstrate in program assessments, external licensure performance, and graduating-student self-report. These perspectives remain distinct so reviewers can understand what each contributes before considering the overall achievement picture.
What evidence am I reviewing?
What students demonstrated through program assessments across Years 1–3 and academic years.
PEBC MCQ and OSCE results provide an external perspective on achievement. The two components remain separate because they use different measures.
AFPC and CCAPP self-report evidence shows how graduating students describe preparedness and where they report developing knowledge and skills.
What do program assessments show about student performance in this stream?
Year one mean scores moved down in each successive academic year, leaving this academic year clearly lower than the previous academic year and two academic years ago.
In the selected academic year Year one has more students in lower score bands and fewer in the top band compared with Years two and three, which sit higher overall.
| PHARM 243 | Year 1 | 2025-2026 | 139 | 74.3% | 74.2% | 8.4% |
| PHARM 243 | Year 1 | 2024-2025 | 134 | 72.6% | 72.6% | 7.8% |
| PHARM 243 | Year 1 | 2023-2024 | 136 | 71.4% | 71.2% | 7.2% |
| PHARM 343 | Year 2 | 2025-2026 | 134 | 72.0% | 72.7% | 9.4% |
| PHARM 343 | Year 2 | 2024-2025 | 133 | 71.2% | 71.3% | 10.2% |
| PHARM 343 | Year 2 | 2023-2024 | 139 | 73.6% | 74.6% | 9.9% |
| PHARM 344 | Year 2 | 2025-2026 | 133 | 71.7% | 72.6% | 7.8% |
| PHARM 344 | Year 2 | 2024-2025 | 133 | 71.0% | 71.5% | 8.3% |
| PHARM 344 | Year 2 | 2023-2024 | 139 | 77.2% | 78.0% | 8.3% |
| PHARM 345 | Year 2 | 2025-2026 | 133 | 77.6% | 77.8% | 6.5% |
| PHARM 345 | Year 2 | 2024-2025 | 133 | 74.8% | 74.7% | 7.5% |
| PHARM 345 | Year 2 | 2023-2024 | 139 | 77.1% | 77.0% | 8.2% |
| PHARM 346 | Year 2 | 2025-2026 | 133 | 73.9% | 73.8% | 7.8% |
| PHARM 346 | Year 2 | 2024-2025 | 133 | 69.6% | 69.6% | 8.4% |
| PHARM 346 | Year 2 | 2023-2024 | 139 | 70.3% | 70.9% | 8.6% |
| PHARM 443 | Year 3 | 2025-2026 | 130 | 78.2% | 78.5% | 8.0% |
| PHARM 443 | Year 3 | 2024-2025 | 135 | 76.5% | 76.7% | 8.3% |
| PHARM 443 | Year 3 | 2023-2024 | 125 | 76.3% | 76.1% | 8.6% |
| PHARM 444 | Year 3 | 2025-2026 | 130 | 75.2% | 75.4% | 8.6% |
| PHARM 444 | Year 3 | 2024-2025 | 135 | 74.6% | 75.6% | 9.8% |
| PHARM 444 | Year 3 | 2023-2024 | 125 | 72.9% | 72.4% | 8.5% |
| PHARM 445 | Year 3 | 2025-2026 | 130 | 75.6% | 76.4% | 7.5% |
| PHARM 445 | Year 3 | 2024-2025 | 135 | 74.7% | 74.3% | 7.8% |
| PHARM 445 | Year 3 | 2023-2024 | 125 | 72.4% | 71.8% | 8.1% |
| PHARM 446 | Year 3 | 2025-2026 | 130 | 78.2% | 77.4% | 7.0% |
| PHARM 446 | Year 3 | 2024-2025 | 135 | 80.8% | 81.0% | 6.1% |
| PHARM 446 | Year 3 | 2023-2024 | 126 | 80.2% | 79.9% | 6.5% |
| PHARM 448 | Year 3 | 2025-2026 | 130 | 69.3% | 69.0% | 7.1% |
| PHARM 448 | Year 3 | 2024-2025 | 135 | 62.6% | 63.5% | 8.2% |
| PHARM 448 | Year 3 | 2023-2024 | 126 | 68.8% | 68.8% | 6.2% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
After being higher two academic years ago, Year one dropped over the subsequent two years and then rose slightly in the selected academic year.
In the selected academic year, Year two scores are lower than in the previous academic year and have moved down from levels two academic years ago.
| PHARM 243 | Year 1 | 2025-2026 | 139 | 74.3% | 74.2% | 8.4% |
| PHARM 243 | Year 1 | 2024-2025 | 134 | 72.6% | 72.6% | 7.8% |
| PHARM 243 | Year 1 | 2023-2024 | 136 | 71.4% | 71.2% | 7.2% |
| PHARM 343 | Year 2 | 2025-2026 | 134 | 72.0% | 72.7% | 9.4% |
| PHARM 343 | Year 2 | 2024-2025 | 133 | 71.2% | 71.3% | 10.2% |
| PHARM 343 | Year 2 | 2023-2024 | 139 | 73.6% | 74.6% | 9.9% |
| PHARM 344 | Year 2 | 2025-2026 | 133 | 71.7% | 72.6% | 7.8% |
| PHARM 344 | Year 2 | 2024-2025 | 133 | 71.0% | 71.5% | 8.3% |
| PHARM 344 | Year 2 | 2023-2024 | 139 | 77.2% | 78.0% | 8.3% |
| PHARM 345 | Year 2 | 2025-2026 | 133 | 77.6% | 77.8% | 6.5% |
| PHARM 345 | Year 2 | 2024-2025 | 133 | 74.8% | 74.7% | 7.5% |
| PHARM 345 | Year 2 | 2023-2024 | 139 | 77.1% | 77.0% | 8.2% |
| PHARM 346 | Year 2 | 2025-2026 | 133 | 73.9% | 73.8% | 7.8% |
| PHARM 346 | Year 2 | 2024-2025 | 133 | 69.6% | 69.6% | 8.4% |
| PHARM 346 | Year 2 | 2023-2024 | 139 | 70.3% | 70.9% | 8.6% |
| PHARM 443 | Year 3 | 2025-2026 | 130 | 78.2% | 78.5% | 8.0% |
| PHARM 443 | Year 3 | 2024-2025 | 135 | 76.5% | 76.7% | 8.3% |
| PHARM 443 | Year 3 | 2023-2024 | 125 | 76.3% | 76.1% | 8.6% |
| PHARM 444 | Year 3 | 2025-2026 | 130 | 75.2% | 75.4% | 8.6% |
| PHARM 444 | Year 3 | 2024-2025 | 135 | 74.6% | 75.6% | 9.8% |
| PHARM 444 | Year 3 | 2023-2024 | 125 | 72.9% | 72.4% | 8.5% |
| PHARM 445 | Year 3 | 2025-2026 | 130 | 75.6% | 76.4% | 7.5% |
| PHARM 445 | Year 3 | 2024-2025 | 135 | 74.7% | 74.3% | 7.8% |
| PHARM 445 | Year 3 | 2023-2024 | 125 | 72.4% | 71.8% | 8.1% |
| PHARM 446 | Year 3 | 2025-2026 | 130 | 78.2% | 77.4% | 7.0% |
| PHARM 446 | Year 3 | 2024-2025 | 135 | 80.8% | 81.0% | 6.1% |
| PHARM 446 | Year 3 | 2023-2024 | 126 | 80.2% | 79.9% | 6.5% |
| PHARM 448 | Year 3 | 2025-2026 | 130 | 69.3% | 69.0% | 7.1% |
| PHARM 448 | Year 3 | 2024-2025 | 135 | 62.6% | 63.5% | 8.2% |
| PHARM 448 | Year 3 | 2023-2024 | 126 | 68.8% | 68.8% | 6.2% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
Year one fell sharply in the academic year two academic years ago and has risen across the two most recent academic years, though still below its initial level.
Compared with the previous academic year, each program year shows fewer students in the lowest band and more clustered in the upper mid-range band.
| PHARM 243 | Year 1 | 2025-2026 | 139 | 74.3% | 74.2% | 8.4% |
| PHARM 243 | Year 1 | 2024-2025 | 134 | 72.6% | 72.6% | 7.8% |
| PHARM 243 | Year 1 | 2023-2024 | 136 | 71.4% | 71.2% | 7.2% |
| PHARM 343 | Year 2 | 2025-2026 | 134 | 72.0% | 72.7% | 9.4% |
| PHARM 343 | Year 2 | 2024-2025 | 133 | 71.2% | 71.3% | 10.2% |
| PHARM 343 | Year 2 | 2023-2024 | 139 | 73.6% | 74.6% | 9.9% |
| PHARM 344 | Year 2 | 2025-2026 | 133 | 71.7% | 72.6% | 7.8% |
| PHARM 344 | Year 2 | 2024-2025 | 133 | 71.0% | 71.5% | 8.3% |
| PHARM 344 | Year 2 | 2023-2024 | 139 | 77.2% | 78.0% | 8.3% |
| PHARM 345 | Year 2 | 2025-2026 | 133 | 77.6% | 77.8% | 6.5% |
| PHARM 345 | Year 2 | 2024-2025 | 133 | 74.8% | 74.7% | 7.5% |
| PHARM 345 | Year 2 | 2023-2024 | 139 | 77.1% | 77.0% | 8.2% |
| PHARM 346 | Year 2 | 2025-2026 | 133 | 73.9% | 73.8% | 7.8% |
| PHARM 346 | Year 2 | 2024-2025 | 133 | 69.6% | 69.6% | 8.4% |
| PHARM 346 | Year 2 | 2023-2024 | 139 | 70.3% | 70.9% | 8.6% |
| PHARM 443 | Year 3 | 2025-2026 | 130 | 78.2% | 78.5% | 8.0% |
| PHARM 443 | Year 3 | 2024-2025 | 135 | 76.5% | 76.7% | 8.3% |
| PHARM 443 | Year 3 | 2023-2024 | 125 | 76.3% | 76.1% | 8.6% |
| PHARM 444 | Year 3 | 2025-2026 | 130 | 75.2% | 75.4% | 8.6% |
| PHARM 444 | Year 3 | 2024-2025 | 135 | 74.6% | 75.6% | 9.8% |
| PHARM 444 | Year 3 | 2023-2024 | 125 | 72.9% | 72.4% | 8.5% |
| PHARM 445 | Year 3 | 2025-2026 | 130 | 75.6% | 76.4% | 7.5% |
| PHARM 445 | Year 3 | 2024-2025 | 135 | 74.7% | 74.3% | 7.8% |
| PHARM 445 | Year 3 | 2023-2024 | 125 | 72.4% | 71.8% | 8.1% |
| PHARM 446 | Year 3 | 2025-2026 | 130 | 78.2% | 77.4% | 7.0% |
| PHARM 446 | Year 3 | 2024-2025 | 135 | 80.8% | 81.0% | 6.1% |
| PHARM 446 | Year 3 | 2023-2024 | 126 | 80.2% | 79.9% | 6.5% |
| PHARM 448 | Year 3 | 2025-2026 | 130 | 69.3% | 69.0% | 7.1% |
| PHARM 448 | Year 3 | 2024-2025 | 135 | 62.6% | 63.5% | 8.2% |
| PHARM 448 | Year 3 | 2023-2024 | 126 | 68.8% | 68.8% | 6.2% |
Calculation note. For each student, exam scores were averaged within each course. Those course averages were then averaged to summarize performance across the stream. Years 1, 2 and 3 are shown separately.
How well are our assessments functioning as measures of student performance?
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Most exams produced generally moderate-to-high reliability, with Year two exams tending toward higher consistency while Year three exams show a wider spread that includes some notably lower-reliability administrations.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Discrimination is most useful because it shows whether students who did better on the rest of the exam were more likely to answer a question correctly and flags low or negative-discrimination items.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Most individual exams cluster at reasonably high reliability, but variability exists—Year three includes some markedly lower exams while Year two reaches higher consistency, so combining assessments can improve stability.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Discrimination — whether better-performing students tended to get a question right — flags items for review, since a notable fraction show low or negative discrimination across years.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
Each dot is one written exam in the selected academic year. Higher values mean the questions on that exam worked together more consistently.
Exam reliability is not course-grade reliability. A final course grade based on several related assessments may be more stable than any one exam, but course-grade reliability is not estimated here.
Individual exams show variability in consistency across years, with Year one tending toward a narrower, more consistently higher range while Year two and Year three include wider spreads and lower minima.
Each dot is one scored question from written exams in the selected academic year. Choose a program year to bring those questions forward while keeping the rest in view.
Discrimination — whether higher-performing students were more likely to answer correctly — most directly flags items that do not track overall exam performance, with Year two and Year three showing relatively more low or negative cases.
One important limit: question functioning and exam consistency tell us how the assessment is behaving. They do not tell us whether the exam adequately covers the intended learning.
How prepared do graduating students say they are, and where do they believe knowledge and skills were developed?
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Care Provider | 2025–26 | |
| 2024–25 | ||
| 2023–24 | ||
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| traditional, complementary, and alternative medicine | |
| nutrition | |
| drugs in pregnancy and lactation | |
| urology | |
| dermatology | |
| hematology | |
| conditions affecting head, eyes, ears, nose, throat (EENT) | |
| rheumatology |
| cardiology | 2026 | 5 | 95 |
| cardiology | 2025 | 5 | 92.4 |
| cardiology | 2024 | 5 | 83 |
| clinical pharmacokinetics | 2025 | 4 | 38.5 |
| clinical pharmacokinetics | 2024 | 4 | 27 |
| complementary and alternative medicines | 2025 | 4 | 43 |
| complementary and alternative medicines | 2024 | 4 | 39 |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 2026 | 5 | 68.8 |
| dermatology | 2026 | 5 | 67.5 |
| dermatology | 2025 | 5 | 69.6 |
| dermatology | 2024 | 5 | 52 |
| drug of abuse and dependency | 2025 | 5 | 69.6 |
| drug of abuse and dependency | 2024 | 5 | 68.4 |
| drugs in pregnancy | 2025 | 5 | 53.2 |
| drugs in pregnancy | 2024 | 4 | 39.4 |
| drugs in pregnancy and lactation | 2026 | 5 | 58.8 |
| endocrine | 2025 | 5 | 83.5 |
| endocrine | 2024 | 5 | 76 |
| endocrinology | 2026 | 5 | 91.1 |
| gastroenterology | 2026 | 5 | 78.5 |
| gastrointestinal | 2025 | 5 | 87.3 |
| gastrointestinal | 2024 | 5 | 76.8 |
| geriatrics | 2025 | 4 | 44.3 |
| geriatrics | 2024 | 4 | 48 |
| hematology | 2026 | 5 | 67.5 |
| hematology | 2025 | 5 | 53.8 |
| hematology | 2024 | 4 | 42 |
| infectious disease | 2026 | 5 | 87.5 |
| infectious disease | 2025 | 5 | 81 |
| infectious disease | 2024 | 5 | 59 |
| nephrology | 2026 | 5 | 86.2 |
| neurology | 2026 | 5 | 85 |
| neurology | 2025 | 5 | 86.1 |
| neurology | 2024 | 5 | 72 |
| nutrition | 2026 | 4 | 43.8 |
| nutrition | 2025 | 4 | 43 |
| nutrition | 2024 | 4 | 41 |
| oncology | 2026 | 5 | 80 |
| oncology | 2025 | 5 | 65.8 |
| oncology | 2024 | 5 | 60 |
| pain | 2026 | 5 | 91.2 |
| pain | 2025 | 5 | 84.8 |
| pain | 2024 | 5 | 75 |
| patient self-care and management of minor ailments | 2026 | 5 | 86.2 |
| pediatrics | 2025 | 4 | 26.6 |
| pediatrics | 2024 | 4 | 28 |
| psychiatric and mental health | 2026 | 5 | 91.2 |
| psychiatry/mental health | 2025 | 5 | 78.2 |
| psychiatry/mental health | 2024 | 5 | 59 |
| pulmonary | 2025 | 5 | 86.1 |
| pulmonary | 2024 | 5 | 73 |
| renal | 2025 | 5 | 75.9 |
| renal | 2024 | 5 | 76 |
| respirology | 2026 | 5 | 87.5 |
| rheumatology | 2026 | 5 | 76.2 |
| rheumatology | 2025 | 5 | 59 |
| rheumatology | 2024 | 4.5 | 50 |
| self care/non-prescription drug-use | 2025 | 5 | 87.3 |
| self care/non-prescription drug-use | 2024 | 5 | 71.7 |
| sexual and reproductive health | 2026 | 5 | 93.8 |
| substance use disorders, dependency, and addiction | 2026 | 5 | 83.8 |
| traditional, complementary, and alternative medicine | 2026 | 4 | 30 |
| urology | 2026 | 5 | 60 |
| women’s and men’s health | 2025 | 5 | 86.1 |
| women’s and men’s health | 2024 | 5 | 76 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Care Provider | 2025–26 | |
| 2024–25 | ||
| 2023–24 | ||
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| traditional, complementary, and alternative medicine | |
| nutrition | |
| drugs in pregnancy and lactation | |
| urology | |
| dermatology | |
| hematology | |
| conditions affecting head, eyes, ears, nose, throat (EENT) | |
| rheumatology |
| cardiology | 2026 | 5 | 95 |
| cardiology | 2025 | 5 | 92.4 |
| cardiology | 2024 | 5 | 83 |
| clinical pharmacokinetics | 2025 | 4 | 38.5 |
| clinical pharmacokinetics | 2024 | 4 | 27 |
| complementary and alternative medicines | 2025 | 4 | 43 |
| complementary and alternative medicines | 2024 | 4 | 39 |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 2026 | 5 | 68.8 |
| dermatology | 2026 | 5 | 67.5 |
| dermatology | 2025 | 5 | 69.6 |
| dermatology | 2024 | 5 | 52 |
| drug of abuse and dependency | 2025 | 5 | 69.6 |
| drug of abuse and dependency | 2024 | 5 | 68.4 |
| drugs in pregnancy | 2025 | 5 | 53.2 |
| drugs in pregnancy | 2024 | 4 | 39.4 |
| drugs in pregnancy and lactation | 2026 | 5 | 58.8 |
| endocrine | 2025 | 5 | 83.5 |
| endocrine | 2024 | 5 | 76 |
| endocrinology | 2026 | 5 | 91.1 |
| gastroenterology | 2026 | 5 | 78.5 |
| gastrointestinal | 2025 | 5 | 87.3 |
| gastrointestinal | 2024 | 5 | 76.8 |
| geriatrics | 2025 | 4 | 44.3 |
| geriatrics | 2024 | 4 | 48 |
| hematology | 2026 | 5 | 67.5 |
| hematology | 2025 | 5 | 53.8 |
| hematology | 2024 | 4 | 42 |
| infectious disease | 2026 | 5 | 87.5 |
| infectious disease | 2025 | 5 | 81 |
| infectious disease | 2024 | 5 | 59 |
| nephrology | 2026 | 5 | 86.2 |
| neurology | 2026 | 5 | 85 |
| neurology | 2025 | 5 | 86.1 |
| neurology | 2024 | 5 | 72 |
| nutrition | 2026 | 4 | 43.8 |
| nutrition | 2025 | 4 | 43 |
| nutrition | 2024 | 4 | 41 |
| oncology | 2026 | 5 | 80 |
| oncology | 2025 | 5 | 65.8 |
| oncology | 2024 | 5 | 60 |
| pain | 2026 | 5 | 91.2 |
| pain | 2025 | 5 | 84.8 |
| pain | 2024 | 5 | 75 |
| patient self-care and management of minor ailments | 2026 | 5 | 86.2 |
| pediatrics | 2025 | 4 | 26.6 |
| pediatrics | 2024 | 4 | 28 |
| psychiatric and mental health | 2026 | 5 | 91.2 |
| psychiatry/mental health | 2025 | 5 | 78.2 |
| psychiatry/mental health | 2024 | 5 | 59 |
| pulmonary | 2025 | 5 | 86.1 |
| pulmonary | 2024 | 5 | 73 |
| renal | 2025 | 5 | 75.9 |
| renal | 2024 | 5 | 76 |
| respirology | 2026 | 5 | 87.5 |
| rheumatology | 2026 | 5 | 76.2 |
| rheumatology | 2025 | 5 | 59 |
| rheumatology | 2024 | 4.5 | 50 |
| self care/non-prescription drug-use | 2025 | 5 | 87.3 |
| self care/non-prescription drug-use | 2024 | 5 | 71.7 |
| sexual and reproductive health | 2026 | 5 | 93.8 |
| substance use disorders, dependency, and addiction | 2026 | 5 | 83.8 |
| traditional, complementary, and alternative medicine | 2026 | 4 | 30 |
| urology | 2026 | 5 | 60 |
| women’s and men’s health | 2025 | 5 | 86.1 |
| women’s and men’s health | 2024 | 5 | 76 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
Graduating students rated how prepared they felt across the statements that make up each professional role. Within each role, read down from the most recent academic year to see how the response distribution has changed over time.
| AFPC professional role | Academic year | Overall graduating-student rating |
|---|---|---|
| Care Provider | 2025–26 | |
| 2024–25 | ||
| 2023–24 | ||
| Scholar | 2025–26 | |
| 2024–25 | ||
| 2023–24 |
Each row pools the six-point ratings across the governed statements contributing to that professional role. Point to or focus a bar for the median and share rated Prepared or Very prepared.
The eight lowest-rated stream-relevant topics in the most recent graduating-student survey are shown as full response distributions. The mean is used only to determine which topics appear.
| Topic | Graduating-student rating |
|---|---|
| traditional, complementary, and alternative medicine | |
| nutrition | |
| drugs in pregnancy and lactation | |
| urology | |
| dermatology | |
| hematology | |
| conditions affecting head, eyes, ears, nose, throat (EENT) | |
| rheumatology |
| cardiology | 2026 | 5 | 95 |
| cardiology | 2025 | 5 | 92.4 |
| cardiology | 2024 | 5 | 83 |
| clinical pharmacokinetics | 2025 | 4 | 38.5 |
| clinical pharmacokinetics | 2024 | 4 | 27 |
| complementary and alternative medicines | 2025 | 4 | 43 |
| complementary and alternative medicines | 2024 | 4 | 39 |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 2026 | 5 | 68.8 |
| dermatology | 2026 | 5 | 67.5 |
| dermatology | 2025 | 5 | 69.6 |
| dermatology | 2024 | 5 | 52 |
| drug of abuse and dependency | 2025 | 5 | 69.6 |
| drug of abuse and dependency | 2024 | 5 | 68.4 |
| drugs in pregnancy | 2025 | 5 | 53.2 |
| drugs in pregnancy | 2024 | 4 | 39.4 |
| drugs in pregnancy and lactation | 2026 | 5 | 58.8 |
| endocrine | 2025 | 5 | 83.5 |
| endocrine | 2024 | 5 | 76 |
| endocrinology | 2026 | 5 | 91.1 |
| gastroenterology | 2026 | 5 | 78.5 |
| gastrointestinal | 2025 | 5 | 87.3 |
| gastrointestinal | 2024 | 5 | 76.8 |
| geriatrics | 2025 | 4 | 44.3 |
| geriatrics | 2024 | 4 | 48 |
| hematology | 2026 | 5 | 67.5 |
| hematology | 2025 | 5 | 53.8 |
| hematology | 2024 | 4 | 42 |
| infectious disease | 2026 | 5 | 87.5 |
| infectious disease | 2025 | 5 | 81 |
| infectious disease | 2024 | 5 | 59 |
| nephrology | 2026 | 5 | 86.2 |
| neurology | 2026 | 5 | 85 |
| neurology | 2025 | 5 | 86.1 |
| neurology | 2024 | 5 | 72 |
| nutrition | 2026 | 4 | 43.8 |
| nutrition | 2025 | 4 | 43 |
| nutrition | 2024 | 4 | 41 |
| oncology | 2026 | 5 | 80 |
| oncology | 2025 | 5 | 65.8 |
| oncology | 2024 | 5 | 60 |
| pain | 2026 | 5 | 91.2 |
| pain | 2025 | 5 | 84.8 |
| pain | 2024 | 5 | 75 |
| patient self-care and management of minor ailments | 2026 | 5 | 86.2 |
| pediatrics | 2025 | 4 | 26.6 |
| pediatrics | 2024 | 4 | 28 |
| psychiatric and mental health | 2026 | 5 | 91.2 |
| psychiatry/mental health | 2025 | 5 | 78.2 |
| psychiatry/mental health | 2024 | 5 | 59 |
| pulmonary | 2025 | 5 | 86.1 |
| pulmonary | 2024 | 5 | 73 |
| renal | 2025 | 5 | 75.9 |
| renal | 2024 | 5 | 76 |
| respirology | 2026 | 5 | 87.5 |
| rheumatology | 2026 | 5 | 76.2 |
| rheumatology | 2025 | 5 | 59 |
| rheumatology | 2024 | 4.5 | 50 |
| self care/non-prescription drug-use | 2025 | 5 | 87.3 |
| self care/non-prescription drug-use | 2024 | 5 | 71.7 |
| sexual and reproductive health | 2026 | 5 | 93.8 |
| substance use disorders, dependency, and addiction | 2026 | 5 | 83.8 |
| traditional, complementary, and alternative medicine | 2026 | 4 | 30 |
| urology | 2026 | 5 | 60 |
| women’s and men’s health | 2025 | 5 | 86.1 |
| women’s and men’s health | 2024 | 5 | 76 |
These are graduating-student self-reports. They describe perceived preparedness and development, not demonstrated competence.
What does PEBC evidence add to the picture of achievement?
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
Within each area, read from the most recent reporting year to earlier reporting years. MCQ average item-difficulty scale. Lower values indicate stronger relative performance on this PEBC measure. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. OSCE competency-rating scale shown on the axis. National values are shown only where they are already available in the governed PEBC evidence. To keep the stream view focused, the figure shows the highest-relevance competencies identified by the governed PEBC-to-AFPC-to-stream crosswalk.
Within each area, read from the most recent reporting year to earlier reporting years. 1–4 OSCE global-rating scale. Higher values indicate stronger ratings. National values are shown only where they are already available in the governed PEBC evidence.
MCQ and OSCE retain their own original measures and scales. Stream relationships establish relevance, not causal attribution.
What becomes clearer when these perspectives are considered together?
When the program performance data, assessment-quality notes, graduating-student AFPC ratings, and PEBC results are viewed together a clearer, practice-oriented picture emerges. Year-over-year exam averages for Years 1–3 rose modestly in 2025–2026, and 2026 graduates report stronger preparedness for the Care Provider role than for Scholar. PEBC’s single-year snapshot is mixed: OSCE competency scores sit at or above national levels for Patient Care and Knowledge, while MCQ competency measures tend to be at or slightly behind national figures in areas such as Quality and Safety, Product Distribution, and Health Promotion. Assessment-quality components are available across program years, with multiple test-level reliability estimates reported.
These sources use different measures, directions, and reporting periods and therefore must be kept separate in interpretation. PEBC MCQ uses a lower-is-better scale while OSCE uses higher-is-better; many test-level reliabilities vary, with some estimates relatively low; and the PEBC and graduate survey items are single-year snapshots. Small numerical differences across these sources should be interpreted cautiously, and the measures should not be pooled or used to make causal claims.
When the program performance data, assessment-quality notes, graduating-student AFPC ratings, and PEBC results are viewed together a clearer, practice-oriented picture emerges. Year-over-year exam averages for Years 1–3 rose modestly in 2025–2026, and 2026 graduates report stronger preparedness for the Care Provider role than for Scholar. PEBC’s single-year snapshot is mixed: OSCE competency scores sit at or above national levels for Patient Care and Knowledge, while MCQ competency measures tend to be at or slightly behind national figures in areas such as Quality and Safety, Product Distribution, and Health Promotion. Assessment-quality components are available across program years, with multiple test-level reliability estimates reported.
These sources use different measures, directions, and reporting periods and therefore must be kept separate in interpretation. PEBC MCQ uses a lower-is-better scale while OSCE uses higher-is-better; many test-level reliabilities vary, with some estimates relatively low; and the PEBC and graduate survey items are single-year snapshots. Small numerical differences across these sources should be interpreted cautiously, and the measures should not be pooled or used to make causal claims.
When the program performance data, assessment-quality notes, graduating-student AFPC ratings, and PEBC results are viewed together a clearer, practice-oriented picture emerges. Year-over-year exam averages for Years 1–3 rose modestly in 2025–2026, and 2026 graduates report stronger preparedness for the Care Provider role than for Scholar. PEBC’s single-year snapshot is mixed: OSCE competency scores sit at or above national levels for Patient Care and Knowledge, while MCQ competency measures tend to be at or slightly behind national figures in areas such as Quality and Safety, Product Distribution, and Health Promotion. Assessment-quality components are available across program years, with multiple test-level reliability estimates reported.
These sources use different measures, directions, and reporting periods and therefore must be kept separate in interpretation. PEBC MCQ uses a lower-is-better scale while OSCE uses higher-is-better; many test-level reliabilities vary, with some estimates relatively low; and the PEBC and graduate survey items are single-year snapshots. Small numerical differences across these sources should be interpreted cautiously, and the measures should not be pooled or used to make causal claims.
What questions does the achievement evidence warrant further consideration?
Where did this information come from, and how was it prepared?
This workspace brings together several different perspectives on achievement for the selected pharmacy stream: performance in program assessments, information about how written exams are functioning, graduating-student self-report, and PEBC licensure results.
These sources answer different questions and are kept separate. Program assessments show performance within the curriculum, graduating-student surveys describe perceived preparedness and development, and PEBC provides an external perspective after the program.
Program-performance figures summarize student exam performance within each course and then across courses in the stream. Program years are shown separately, and the most recent academic year can be compared with earlier academic years using the same calculation.
Assessment-quality figures provide additional context about how individual written exams and exam questions are functioning. Exam reliability and item statistics can help identify results that deserve closer review, but they do not establish whether an exam adequately covers the intended curriculum.
Exam reliability describes an individual assessment, not the reliability of a final course grade that combines several assessments.
AFPC professional-role preparedness and CCAPP knowledge-and-skill development use six-point response scales. The coloured bars show the full distribution of student responses rather than reducing the result to a single score. Hover or keyboard focus provides the median and the share of responses in the two most favourable categories.
The professional-role figure compares the same role across available survey years. The knowledge-and-skill figure shows the eight lowest-rated stream-relevant topics in the most recent survey; the mean is used only to select those topics, while the displayed evidence remains the full response distribution.
These are student self-reports. They complement demonstrated achievement evidence but are not treated as direct measures of competence.
PEBC results are displayed on their original assessment-specific scales. MCQ competency results, OSCE competency results, and the available 1–4 OSCE global ratings are shown separately. Within each figure, the most recent reporting year appears first so changes can be followed over time.
UAlberta results are shown alongside the national value when that comparison already exists in the governed PEBC evidence. Missing national values are left absent rather than reconstructed.
PEBC reporting years are not treated as equivalent to the academic-cycle selector, and relationships to a stream establish relevance rather than showing that the stream caused the result.
The report first prepares the quantitative evidence and its source-specific limits. AI-assisted writing is then used to create concise educator-facing What stands out notes, cross-evidence orientation, and review questions from those prepared records.
AI-assisted writing does not calculate the figures, combine unlike scales, decide whether learning outcomes have been achieved, determine why a pattern occurred, or recommend curriculum changes. Those judgments remain with the educators reviewing the evidence.
The written summaries are prepared before the report is displayed. Opening or browsing this report does not send a new request to an AI service.
A visible difference between academic years, survey years, or PEBC reporting years does not by itself establish an educationally important improvement or decline. Each source should first be interpreted on its own scale and within its own reporting period.
When evidence is missing, not comparable, unavailable for a stream, or reported on a different scale, the workspace keeps that limitation visible rather than filling the gap or creating a combined achievement score.